Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:FDY's 5-Year Yield-on-Cost % is ranked worse than 75.15% of 515
companies
in the Drug Manufacturers industry
Industry Median: 2.25
vs FRA:FDY: 0.81
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
FRA:FDY vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a 5-Year Yield-on-Cost % of 0.81 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. This is 58% below median its historical median of 1.92. Over the past decade, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 0.32 to 2.73. According to the industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #387 out of 515 companies in the Drug Manufacturers industry, placing it in the top 75.1%.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current 5-Year Yield-on-Cost % of 0.81 is 58% below median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 2.73. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.25. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's value of 0.81 is 64% below this industry median. Based on the distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #387 out of 515 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #387 out of 515 companies for 5-Year Yield-on-Cost %. This places Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's value of 0.81 is 64% below this benchmark. Historically, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 0.32 to 2.73 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 2.25, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current 5-Year Yield-on-Cost % of 0.81 is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current 5-Year Yield-on-Cost % is 0.81, which is 58% below median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current 5-Year Yield-on-Cost % of 0.81. The stock's GF Value™ is €0.24, compared to a current price of €0.27 — trading 10.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.81, which is 58% below median its 10-year median of 1.92 and 64% below the Drug Manufacturers industry median of 2.25. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current 5-Year Yield-on-Cost % is 0.81 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of €0.27 is trading 10.8% above its estimated GF Value™ of €0.24.
Key valuation signals for FRA:FDY:
5-Year Yield-on-Cost %: 0.81 (58% below median its 10-year median of 1.92)
GF Value™: €0.24 vs. price of €0.27 (10.8% above fair value)
Industry Position: 64% below the Drug Manufacturers median (#387 of 515)
No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
69GF Score
Get the complete analysis for FRA:FDY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FDY has been successfully added to your 
